(Q37076279)

18 August 2017

Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research (English)

1 reference

18 August 2017

0 references

0 references

Robert P McMahon

1

1 reference

18 August 2017

Deanna L Kelly

2

1 reference

18 August 2017

Douglas L Boggs

3

1 reference

18 August 2017

Lan Li

4

1 reference

18 August 2017

Qiaoyan Hu

5

1 reference

18 August 2017

John M Davis

6

1 reference

18 August 2017

William T Carpenter

7

1 reference

18 August 2017

language of work or name

English

0 references

publication date

8 January 2008

1 reference

18 August 2017

Schizophrenia Bulletin

1 reference

18 August 2017

34

1 reference

18 August 2017

2

1 reference

18 August 2017

292-301

1 reference

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

Alternatives to placebo-controlled trials

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

The "delayed onset" of antipsychotic action--an idea whose time has come and gone.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

Analyzing incomplete longitudinal clinical trial data

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

The revision of the Declaration of Helsinki: past, present and future

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

Placebo or Active Control Trials of Antipsychotic Drugs?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

Assessing and interpreting treatment effects in longitudinal clinical trials with missing data

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

Benefits and burdens of placebos in psychiatric research

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

Placebo control groups in randomized treatment trials: a statistician's perspective

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

The long-term effects of placebo in patients with chronic schizophrenia.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

The need to revise the Declaration of Helsinki

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

Placebo-controlled trials in schizophrenia: are they ethical? Are they necessary?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

Optimizing early prediction for antipsychotic response in schizophrenia.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

An inverse relationship between perceived harm and participation willingness in schizophrenia research protocols.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

Evidence for onset of antipsychotic effects within the first 24 hours of treatment

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

Quetiapine in schizophrenia: onset of action within the first week of treatment

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

Attitudes of patients with schizophrenia toward placebo-controlled clinical trials.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

The use of placebo control groups in the assessment of psychiatric drugs: an historical context.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

Subject selection for the placebo- and comparator-controlled trials of neuroleptics in schizophrenia.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

Placebo in research on schizophrenia.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632413

Feasibility of placebo-controlled clinical trials of antipsychotic compounds in Europe

4 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18184634

12 December 2020

inferred from PubMed ID database lookup

A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18184634

12 December 2020

inferred from PubMed ID database lookup

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18184634

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1093/SCHBUL/SBM152

1 reference

release_225q23r4ynhstaolfe2lvwbbgy

18 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/225q23r4ynhstaolfe2lvwbbgy

24 November 2022

mapped directly with Wikidata item

1 reference

18 August 2017

1 reference